Tourmaline Bio

Thyroid eye disease (TED) treatment is advancing with IL-6 targeting therapies like pacibekitug, aiming for durable disease control by addressing autoimmune inflammation's root causes, beyond current symptom-focused treatments.

In 2025, genetic validation will be crucial in cardiovascular R&D, investors will focus on proven science, and patients will be more active in healthcare. Precision medicine and genetic data will drive drug development, with data becoming the gold standard for investments. Real-world data (RWD) integration will transform clinical trials, enhancing patient control over medical records.

Tourmaline Bio's Phase 2 TRANQUILITY trial exceeds enrollment with 143 patients; topline data expected Q2 2025. Deepak L. Bhatt and Dipender Gill join the Cardiovascular Scientific Advisory Board. Abdominal aortic aneurysm nominated as a new indication for pacibekitug, expanding its development for inflammation-driven cardiovascular disease.

Tourmaline Bio to host virtual Investor Day on Dec 10, 2024, featuring updates on pacibekitug development.

DelveInsight's 'Hematopoietic Stem Cell Transplantation Pipeline Insight, 2024' report details 20+ companies developing therapies, including Orchard Therapeutics, Lisata Therapeutics, Genenta science, and Editas Medicine. Key therapies in clinical trials are OTL-204, OTL-105, LSTA201, Temferon, and EDIT-301. The report covers mechanism of action, route of administration, and market dynamics.

Tourmaline Bio to present two posters at the 19th Annual Cardiometabolic Health Congress, highlighting inflammatory cardiovascular risk and IL-6 inhibition mechanisms.

Tourmaline Bio to present two posters on inflammatory cardiovascular risk and IL-6 inhibition at the 19th Annual Cardiometabolic Health Congress in Boston, Oct 17-19, 2024.